Optimized Xenograft Protocol for Chronic Lymphocytic Leukemia Results in High Engraftment Efficiency for All CLL Subgroups

Preclinical drug development for human chronic lymphocytic leukemia (CLL) requires robust xenograft models recapitulating the entire spectrum of the disease, including all prognostic subgroups. Current CLL xenograft models are hampered by inefficient engraftment of good prognostic CLLs, overgrowth w...

Descripción completa

Detalles Bibliográficos
Autores principales: Decker, Sarah, Zwick, Anabel, Khaja Saleem, Shifa, Kissel, Sandra, Rettig, Andres, Aumann, Konrad, Dierks, Christine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6940872/
https://www.ncbi.nlm.nih.gov/pubmed/31842407
http://dx.doi.org/10.3390/ijms20246277

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6940872/
https://www.ncbi.nlm.nih.gov/pubmed/31842407
http://dx.doi.org/10.3390/ijms20246277

Ejemplares similares